Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells $437,700.00 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Richard K. Prins sold 10,000 shares of the company’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $43.77, for a total transaction of $437,700.00. Following the completion of the sale, the director now owns 30,471 shares of the company’s stock, valued at approximately $1,333,715.67. This trade represents a 24.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Amphastar Pharmaceuticals Stock Down 5.1 %

Shares of Amphastar Pharmaceuticals stock opened at $42.24 on Friday. Amphastar Pharmaceuticals, Inc. has a one year low of $36.56 and a one year high of $65.92. The company has a market cap of $2.03 billion, a P/E ratio of 14.08, a PEG ratio of 0.87 and a beta of 0.78. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The firm has a fifty day moving average of $47.14 and a two-hundred day moving average of $44.61.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 target price for the company. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Amphastar Pharmaceuticals has an average rating of “Hold” and a consensus price target of $60.33.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. boosted its holdings in Amphastar Pharmaceuticals by 22.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 189,605 shares of the company’s stock valued at $7,584,000 after purchasing an additional 35,306 shares in the last quarter. Ellsworth Advisors LLC boosted its stake in shares of Amphastar Pharmaceuticals by 6.4% in the second quarter. Ellsworth Advisors LLC now owns 86,391 shares of the company’s stock valued at $3,456,000 after buying an additional 5,226 shares in the last quarter. Blue Trust Inc. grew its holdings in Amphastar Pharmaceuticals by 23.9% during the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after acquiring an additional 309 shares during the period. Oakworth Capital Inc. purchased a new position in Amphastar Pharmaceuticals in the second quarter worth $201,000. Finally, Raymond James & Associates lifted its holdings in Amphastar Pharmaceuticals by 16.9% in the second quarter. Raymond James & Associates now owns 114,719 shares of the company’s stock valued at $4,589,000 after acquiring an additional 16,574 shares during the period. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.